Literature DB >> 32546734

Reply to 'Personalized treatment of immune-related adverse events - balance is required'.

Kashayar Esfahani1, Leonard Calabrese2.   

Abstract

Mesh：

Year:  2020        PMID： 32546734     DOI： 10.1038/s41571-020-0401-3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Personalized treatment of immune-related adverse events - balance is required.

Authors:  Filipe Martins; Michel Obeid
Journal:  Nat Rev Clin Oncol       Date:  2020-08       Impact factor: 66.675

2.  Reply to 'Personalized treatment of immune-related adverse events - balance is required'.

Authors:  Kashayar Esfahani; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-08       Impact factor: 66.675
  2 in total
  4 in total

1.  Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.

Authors:  Kevin Tyan; Joanna Baginska; Martha Brainard; Anita Giobbie-Hurder; Mariano Severgnini; Michael Manos; Rizwan Haq; Elizabeth I Buchbinder; Patrick A Ott; F Stephen Hodi; Osama E Rahma
Journal:  Cancer Immunol Immunother       Date:  2021-01-22       Impact factor: 6.968

2.  Personalized treatment of immune-related adverse events - balance is required.

Authors:  Filipe Martins; Michel Obeid
Journal:  Nat Rev Clin Oncol       Date:  2020-08       Impact factor: 66.675

3.  Reply to 'Personalized treatment of immune-related adverse events - balance is required'.

Authors:  Kashayar Esfahani; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-08       Impact factor: 66.675

Review 4.  Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).

Authors:  Tao Wang; Matthew M Yeh; Mark I Avigan; Lorraine Pelosof; Gerald M Feldman
Journal:  AAPS J       Date:  2021-08-16       Impact factor: 4.009
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.